Keryx Biopharmaceuticals  

(Public, NASDAQ:KERX)   Watch this stock  
Find more results for Brian Fischer
+0.10 (1.82%)
Nov 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.46 - 5.88
52 week 3.04 - 16.50
Open 5.49
Vol / Avg. 1.20M/2.26M
Mkt cap 588.03M
P/E     -
Div/yield     -
EPS -1.26
Shares 105.19M
Beta 3.59
Inst. own 86%
Feb 25, 2016
Q4 2015 Keryx Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2015
Keryx Biopharmaceuticals Inc at Stifel Healthcare Conference
Nov 10, 2015
Keryx Biopharmaceuticals Inc at Credit Suisse Healthcare Conference
Oct 29, 2015
Q3 2015 Keryx Biopharmaceuticals Inc Earnings Release
Oct 29, 2015
Q3 2015 Keryx Biopharmaceuticals Inc Earnings Call - Webcast
Sep 29, 2015
Keryx Biopharmaceuticals Inc at Ladenburg Thalmann Life Sciences Conference
Sep 17, 2015
Keryx Biopharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 9, 2015
Keryx Biopharmaceuticals Inc at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -730.63% -1030.19%
Operating margin -732.49% -1027.52%
EBITD margin - -1024.69%
Return on average assets -74.33% -135.67%
Return on average equity -91.96% -187.61%
Employees 155 -
CDP Score - -


750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-212-5315965 (Phone)
+1-212-5315961 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxia's pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).

Officers and directors

Michael P. Tarnok Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Gregory P. Madison Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Scott A. Holmes Chief Financial Officer
Age: 40
Bio & Compensation  - Reuters
Brian R. Adams Vice President, General Counsel
Age: 41
Bio & Compensation  - Reuters
Abraham Ceesay Vice President of Marketing
Bio & Compensation  - Reuters
John F. Neylan Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Lauren Fischer Director
Bio & Compensation  - Reuters
Kevin J. Cameron Independent Director
Age: 46
Bio & Compensation  - Reuters
Joseph M. Feczko M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Wyche Fowler Jr., J.D Independent Director
Age: 74
Bio & Compensation  - Reuters